Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000898432-23-000326
Filing Date
2023-05-22
Accepted
2023-05-22 16:34:00
Documents
43
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 blac-20230331.htm   iXBRL 10-Q 539551
2 exh31-1.htm EX-31.1 15410
3 exh31-2.htm EX-31.2 15400
4 exh32-1.htm EX-32.1 7826
5 exh32-2.htm EX-32.2 7472
  Complete submission text file 0000898432-23-000326.txt   3008301

Data Files

Seq Description Document Type Size
6 blac-20230331.xsd EX-101.SCH 40688
7 blac-20230331_cal.xml EX-101.CAL 15075
8 blac-20230331_def.xml EX-101.DEF 173064
9 blac-20230331_lab.xml EX-101.LAB 278142
10 blac-20230331_pre.xml EX-101.PRE 178921
37 EXTRACTED XBRL INSTANCE DOCUMENT blac-20230331_htm.xml XML 237705
Mailing Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004
Business Address 10900 NE 4TH STREET, SUITE 2300 BELLEVUE WA 98004 425-635-7700
Bellevue Life Sciences Acquisition Corp. (Filer) CIK: 0001840425 (see all company filings)

EIN.: 845052822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41390 | Film No.: 23945014
SIC: 6770 Blank Checks